Champions Oncology Company Insiders
| CSBR Stock | USD 4.31 0.02 0.46% |
Champions Oncology's insiders are aggressively buying. The analysis of insiders' sentiment of trading Champions Oncology stock suggests that virtually all insiders are extremely bullish at this time. Champions Oncology employs about 210 people. The company is managed by 10 executives with a total tenure of roughly 490 years, averaging almost 49.0 years of service per executive, having 21.0 employees per reported executive.
Champions Oncology's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-01-12 | Daniel Newman Mendelson | Acquired 1000 @ 6.5 | View | ||
| 2024-01-10 | Daniel Newman Mendelson | Acquired 2944 @ 6.31 | View | ||
| 2024-01-08 | Daniel Newman Mendelson | Acquired 1000 @ 6.15 | View | ||
| 2024-01-05 | Daniel Newman Mendelson | Acquired 2000 @ 6.09 | View | ||
| 2024-01-03 | Daniel Newman Mendelson | Acquired 500 @ 5.83 | View | ||
| 2023-12-21 | Daniel Newman Mendelson | Acquired 2500 @ 4.92 | View | ||
| 2023-12-19 | Daniel Newman Mendelson | Acquired 5000 @ 4.75 | View |
Monitoring Champions Oncology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Champions |
Champions Oncology's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Champions Oncology's future performance. Based on our forecasts, it is anticipated that Champions will maintain a workforce of slightly above 210 employees by December 2024.Champions Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.0693) % which means that it has lost $0.0693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.3246) %, meaning that it created substantial loss on money invested by shareholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Equity is likely to grow to 4.01, while Return On Tangible Assets are likely to drop (0.30). At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 11/29/2024, Non Current Assets Total is likely to grow to about 13.1 M, while Intangible Assets are likely to drop slightly above 650.6 K.As of 11/29/2024, Common Stock Shares Outstanding is likely to grow to about 14.2 M, while Net Loss is likely to drop (6.4 M).
Champions Oncology Workforce Comparison
Champions Oncology is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,159. Champions Oncology retains roughly 210 in number of employees claiming about 18% of equities under Health Care industry.
Champions Oncology Profit Margins
The company has Profit Margin (PM) of (0.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.53 | 0.4138 |
|
|
Champions Oncology Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Champions Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Champions Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Champions Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 2 | 2 | 105,137 | 105,137 |
| 2023-12-01 | 18.0 | 18 | 1 | 473,342 | 14,552 |
| 2022-12-01 | 1.375 | 11 | 8 | 166,757 | 60,456 |
| 2021-12-01 | 9.0 | 9 | 1 | 109,082 | 10,000 |
| 2021-03-01 | 1.0 | 5 | 5 | 43,040 | 35,507 |
| 2020-12-01 | 2.0 | 8 | 4 | 82,500 | 68,210 |
| 2020-03-01 | 1.3846 | 18 | 13 | 1,588,742 | 2,295,651 |
| 2019-12-01 | 8.0 | 8 | 1 | 266,444 | 1,521 |
| 2019-03-01 | 5.0 | 5 | 1 | 129,167 | 4,167 |
| 2018-12-01 | 1.6 | 8 | 5 | 183,333 | 443,137 |
| 2016-09-01 | 3.125 | 25 | 8 | 1,446,084 | 585,546 |
| 2015-03-01 | 12.5 | 25 | 2 | 45,564,638 | 10,312,500 |
| 2013-03-01 | 7.0 | 14 | 2 | 17,585,376 | 1,000,000 |
| 2012-03-01 | 1.0 | 3 | 3 | 150,000 | 328,333 |
| 2011-06-01 | 0.5 | 1 | 2 | 3,100,000 | 5,100,000 |
| 2010-09-01 | 1.0 | 1 | 1 | 50,000 | 93,921 |
| 2010-03-01 | 4.0 | 4 | 1 | 350,000 | 85,227 |
| 2009-09-01 | 2.0 | 4 | 2 | 188,526 | 126,562 |
| 2009-03-01 | 1.0 | 1 | 1 | 233,000 | 200,000 |
| 2008-03-01 | 0.5714 | 4 | 7 | 190,000 | 1,800,000 |
| 2007-06-01 | 1.0 | 1 | 1 | 3,800,000 | 0.00 |
| 2007-03-01 | 0.5 | 1 | 2 | 50,000 | 50,000 |
Champions Oncology Notable Stakeholders
A Champions Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Champions Oncology often face trade-offs trying to please all of them. Champions Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Champions Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ronnie MD | CEO Director | Profile | |
| Brady Davis | President | Profile | |
| MBA MS | VP Marketing | Profile | |
| Marianna Zipeto | Research Commercial | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Maria Mancini | Chief Operations | Profile | |
| Karin Heidemann | Executive Operations | Profile | |
| Arthur Hanson | Vice Technology | Profile | |
| BS CMAR | Ex Operations | Profile | |
| David MBA | Chief Officer | Profile |
About Champions Oncology Management Performance
The success or failure of an entity such as Champions Oncology often depends on how effective the management is. Champions Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Champions management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Champions management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (1.60) | (1.68) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | 3.82 | 4.01 |
Champions Oncology Workforce Analysis
Traditionally, organizations such as Champions Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Champions Oncology within its industry.Champions Oncology Manpower Efficiency
Return on Champions Oncology Manpower
| Revenue Per Employee | 238.8K | |
| Revenue Per Executive | 5M | |
| Net Loss Per Employee | 34.6K | |
| Net Loss Per Executive | 727.6K |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.